Literature DB >> 10623816

Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells.

L Lefrançois1, J D Altman, K Williams, S Olson.   

Abstract

The signals directing induction of tolerance rather than immunity are largely unknown. The CD8 T cell response to soluble Ags generally results in deletional tolerance following transient, costimulation-dependent activation. We demonstrated that CD40 signaling reversed the outcome of this response. Adoptive transfer of OVA-specific CD8 T cells followed by soluble OVA immunization resulted in induction of lytic activity and optimal clonal expansion only when CD40 was triggered via an agonistic mAb. Activation of CD8 T cells by CD40 signaling was indirect, because CD40 expression by host cells was required. CD40 signaling along with soluble Ag immunization also induced expansion of secondary lymphoid and intestinal mucosal endogenous OVA-specific CD8 T cells as detected by MHC tetramer reactivity. When CD40 activation was included, long-lived secondary lymphoid and mucosal memory CD8 cells were generated from adoptively transferred and endogenous CD8 T cells. Mucosal and peripheral CD8 memory cells exhibited constitutive Ag-specific lytic activity, with mucosal memory cells being 10-fold more lytic than splenic or lymph node memory cells. These results demonstrated that CD40 signaling during a response to a poorly immunogenic soluble Ag was necessary and sufficient for CTL and memory T cell induction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623816     DOI: 10.4049/jimmunol.164.2.725

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  New developments in autologous tumor cell vaccination therapy for renal cell carcinoma.

Authors:  A J van den Eertwegh ; H M Pinedo
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

2.  Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice.

Authors:  Gabrielle T Belz; Dominik Wodarz; Gabriela Diaz; Martin A Nowak; Peter C Doherty
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Rescue of CD8 T cell-mediated antimicrobial immunity with a nonspecific inflammatory stimulus.

Authors:  Roman A Tuma; Rielle Giannino; Patrick Guirnalda; Ingrid Leiner; Eric G Pamer
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

4.  T cell and APC dynamics in situ control the outcome of vaccination.

Authors:  Kamal M Khanna; David A Blair; Anthony T Vella; Stephen J McSorley; Sandip K Datta; Leo Lefrançois
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

5.  Co-administration of CD40 agonistic antibody and antigen fails to overcome the induction of oral tolerance.

Authors:  Yeonseok Chung; Dong-Hyeon Kim; Seung-Ho Lee; Chang-Yuil Kang
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

6.  Cutting edge: latecomer CD8 T cells are imprinted with a unique differentiation program.

Authors:  Warren N D'Souza; Stephen M Hedrick
Journal:  J Immunol       Date:  2006-07-15       Impact factor: 5.422

7.  Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection.

Authors:  Joshua J Obar; Kamal M Khanna; Leo Lefrançois
Journal:  Immunity       Date:  2008-05-22       Impact factor: 31.745

8.  Splenic priming of virus-specific CD8 T cells following influenza virus infection.

Authors:  Damian L Turner; Kara L Bickham; Donna L Farber; Leo Lefrançois
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

Review 9.  TNF superfamily: costimulation and clinical applications.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Cell Biol Int       Date:  2009-02-20       Impact factor: 3.612

10.  CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals.

Authors:  Jun Liu; Qigui Yu; Geoffrey W Stone; Feng Yun Yue; Nicholas Ngai; R Brad Jones; Richard S Kornbluth; Mario A Ostrowski
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.